Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.38 |
| ▸ | NPC1 | O15118 | 5/20 | 0.38 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | GRM1 | Q13255 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.33 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3406917 | 0.83 | ALDH1A1 (0.46) | RAB9ANPC1MAPTMEN1KMT2A | |
| SCHEMBL3400971 | 0.81 | ALDH1A1 (0.45) | RAB9AMAPTMEN1KMT2ALMNA | |
| SCHEMBL3405606 | 0.81 | ECE1 (0.46) | RAB9ANPC1MAPTMEN1KMT2A | |
| SCHEMBL3406920 | 0.72 | ALDH1A1 (0.43) | RAB9ANPC1MAPTKMT2ALMNA | |
| SCHEMBL13993307 | 0.71 | ALDH1A1 (0.37) | RAB9ANPC1MAPTMEN1KMT2A | |
| SCHEMBL3402617 | 0.70 | BRD4 (0.37) | RAB9ANPC1MAPTMEN1KMT2A | |
| SCHEMBL3402237 | 0.70 | LMNA (0.44) | RAB9ANPC1MAPTMEN1KMT2A | |
| SCHEMBL11278098 | 0.70 | LMNA (0.64) | MEN1KMT2ALMNAALDH1A1RXFP1 | |
| SCHEMBL11289442 | 0.70 | MAPT (0.52) | RAB9ANPC1MAPTKMT2ALMNA | |
| SCHEMBL3406697 | 0.69 | ECE1 (0.44) | MAPTMEN1KMT2ALMNAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2158199-B1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-11-17 | — | — | EP | disclosed |
| EP-2158199-B1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2010-11-17 | — | — | EP | disclosed |
| WO-2008152418-A1 | PIPERIDINE COMPOUNDS AND USES THEREOF | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | WO | disclosed |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | ASTRAZENECA AB (SE) | 2008-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312255-A1 | PIPERDINE COMPOUNDS AND USES THEREOF-911 | NISCH, PIR, QDPR | RAB9A 399/4885NPC1 789/4885MAPT 2837/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.